---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-012510"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:49:52.131590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance

## Summary
- Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.
- Net income $1.8M ($0.06 EPS) vs net loss of $3.3M ($0.14 loss) in prior year.
- Product gross margin improved to 58.9% from 27.2%; FY2025 product revenue outlook $8-10M reaffirmed.
- Regained Nasdaq compliance; debt-free with $1.1M cash and $4.1M working capital.
- OneRF placed in 5 epilepsy centers; FDA 510(k) submission for trigeminal nerve ablation expected H1 2025.

## SEC filing metadata
- accession: 0001213900-25-012510
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/0001213900-25-012510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/ea0230716-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-012510
- JSON: https://secwatch.observer/filing/0001213900-25-012510.json
- Plain text: https://secwatch.observer/filing/0001213900-25-012510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.